Ascendis Pharma, Inc.
500 Emerson Street
Fax: 650-618 -592
165 articles about Ascendis Pharma, Inc.
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
Ascendis Pharma A/S announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets.
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
Ascendis Pharma A/S announced that YORVIPATH®, a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria.
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
Ascendis Pharma A/S announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa ™ and Yorvipath ™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain.
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd has added three new endocrinology therapies to its specialist portfolio, following an exclusive distribution agreement with Danish company Ascendis Pharma A/S.
Ascendis Pharma A/S introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030.
Ascendis Pharma A/S announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research & Product Development, will participate in the 42nd Annual J.P. Morgan Healthcare Conference.
Ascendis Pharma A/S announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
Ascendis Pharma A/S announced that the European Commission has granted marketing authorization for YORVIPATH® as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.
Ascendis Pharma A/S presented a poster with results of a sub-analysis of its Phase 3 PaTHway clinical trial data during the recent American Thyroid Association annual meeting, showing that 81% of adults with chronic post-surgical hypoparathyroidism treated with TransCon PTH achieved independence from conventional calcium and active vitamin D therapy while maintaining normal serum calcium levels during the 26-week blinded portion of the trial, compared to 6% taking placebo.
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
Ascendis Pharma A/S announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency.
Ascendis Pharma A/S and Royalty Pharma plc announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue.
Ascendis Pharma A/S announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice President & Chief Financial Officer, will participate in three upcoming investor conferences.
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
Ascendis Pharma A/S reported one-year data from its ongoing Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism.
Ascendis Pharma A/S announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.
Ascendis Pharma A/S announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time.
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
Ascendis Pharma A/S announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormone deficiency, and host informational booth and events, at ECE 2023, the European Congress of Endocrinology being held May 13-16 in Istanbul, Turkey.
This week, the FDA will release its verdict on Biogen and Ionis’ ALS candidate tofersen and three other investigational medicines for psychiatric disorders, hormonal insufficiency and gut infection.
Ascendis Pharma A/S announced financial results for the full year ended December 31, 2022 and provided a business update.
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S provided an update on its Vision 3x3 strategic roadmap and planned 2023 key corporate milestones.